Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration
Sponsor: |
Ohr Pharmaceutical, Inc. |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAQ6799 |
U.S. Govt. ID: |
NCT02727881 |
Contact: |
Maribel Rodriguez: 212-305-1407 / mr3208@cumc.columbia.edu |
Macular degeneration is a progressive eye disease that damages the macula. The macula is the part of the eye that is responsible for central vision, which is needed to perform straight-ahead activities, such as reading, driving, or watching TV. This research is being conducted to learn about the safety and efficacy (how effectively the study drug works) of a drug (an eye drop) called Squalamine Lactate Ophthalmic Solution, 0.2% given in conjunction with an injection into the eye of Lucentis which is the standard-of-care for the treatment of wet-AMD.
This study is closed
Investigator
Tongalp Tezel, MD
Have you been diagnosed with AMD (Age related Macular Degeneration)? |
Yes |
No |
Are you 50 years of age or over? |
Yes |
No |